Evidence map›Paper›PMID 34560199›Full record

ReviewBiochimica et biophysica acta. Reviews on cancer2021

Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies.

Andrew Cannon, Christopher M Thompson, Rakesh Bhatia, Rakhee R K Kandy, Joyce C Solheim, Surinder K Batra, Sushil Kumar

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta. Reviews on cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. The role of CXC chemokines and receptors in breast cancer.Clinical and experimental medicine · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andrew CannonDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America.
Christopher M ThompsonDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America.
Rakesh BhatiaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America.
Rakhee R K KandyDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America.
Joyce C SolheimDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America; Eppley Institute for Research in Cancer and Allied Diseases: University of Nebraska Medical Center, Omaha, NE 68198, United States of America; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, United States of America.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America; Eppley Institute for Research in Cancer and Allied Diseases: University of Nebraska Medical Center, Omaha, NE 68198, United States of America; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, United States of America. Electronic address: sbatra@unmc.edu.
Sushil KumarDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, United States of America. Electronic address: skumar@unmc.edu.
University of Nebraska Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PHILIBERT, INGRID · 2016 to 2025
$42.8M
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC MetastasisP01CA217798 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI THAYER, SARAH P · 2018 to 2022
$8.1M
Ignite-Engage-Sustain: A Comprehensive Approach to Motivate, Involve, Educate, and Mentor Native American Students and Their Communities in Cancer Prevention, Treatment and ResearchR25CA221777 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI MAURICE GODFREY, Regina Emily Idoate · 2017 to 2026
$4.0M
Role of PD2/Paf1 in Pancreatic Acinar to Ductal MetaplasiaR01CA210637 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., PONNUSAMY, MOORTHY P. · 2017 to 2021
$2.0M
Targeting CXCR2 axis in Pancreatic CancerR01CA228524 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., SINGH, RAKESH K · 2018 to 2022
$2.0M
Targeting LIF/LIFR in pancreatic cancerR44CA235991 · NCI · EVESTRA, INC. · PI KUMAR, SUSHIL, NAIR, HAREESH BABU · 2019 to 2021
$1.7M
Impaired phospholipid methylation results in decreased lipid droplet lipolysis: Role in hepatic steatosisR01AA026723 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KHARBANDA, KUSUM K. · 2018 to 2022
$1.6M
Targeting Mucin and EGFR Axis in Pancreatic CancerR01CA183459 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2014 to 2018
$1.6M
Alcohol and smoking concurrently aggravate chronic pancreatitisR21AA026428 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KHARBANDA, KUSUM K., KUMAR, SUSHIL · 2017 to 2018
$397k
New Strategy for Pancreatic Cancer TherapyR21CA223429 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SOLHEIM, JOYCE C · 2018 to 2019
$358k
CXCR3 in Pancreatic Cancer Progression and MetastasisF30CA225117 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CANNON, ANDREW C · 2018 to 2020
$101k
NCI NIH HHS F30 CA225117NCI NIH HHS F31 CA243469NCI NIH HHS P01 CA217798NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA183459NCI NIH HHS R01 CA210637NCI NIH HHS R01 CA228524NCI NIH HHS R21 CA223429NCI NIH HHS R25 CA221777NCI NIH HHS R44 CA235991NIAAA NIH HHS R01 AA026723NIAAA NIH HHS R21 AA026428NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

Metastasis is a significant cause of the mortality resulting from solid malignancies. The process of metastasis is complex and is regulated by numerous cancer cell-intrinsic and -extrinsic factors. CXCR3 is a chemokine receptor that is frequently expressed by cancer cells, endothelial cells and immune cells. CXCR3A signaling in cancer cells tends to promote the invasive and migratory phenotype of cancer cells. Indirectly, CXCR3 modulates the anti-tumor immune response resulting in variable effects that can permit or inhibit metastatic progression. Finally, the activity of CXCR3B in endothelial cells is generally angiostatic, which limits the access of cancer cells to key conduits to secondary sites. However, the interaction of these activities within a tumor and the presence of opposing CXCR3 splice variants clouds the picture of the role of CXCR3 in metastasis. Consequently, thorough analysis of the contributions of CXCR3 to cancer metastasis is necessary. This review is an in-depth examination of the involvement of CXCR3 in the metastatic process of solid malignancies.

Indexed as

HumansNeoplasm MetastasisNeoplasmsReceptors, CXCR3Signal TransductionCXCR3 protein, humanReceptors, CXCR3cancerCXCR3CytokinesMetastasisTumor microenvironment

Identifiers

PMID34560199
PMCPMC8595872
OpenAlexW3200440551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.